Allergan plc (NYSE:AGN) Position Trimmed by Ingalls & Snyder LLC

Ingalls & Snyder LLC decreased its holdings in shares of Allergan plc (NYSE:AGN) by 1.4% in the 4th quarter, Holdings Channel reports. The firm owned 7,059 shares of the company’s stock after selling 100 shares during the quarter. Ingalls & Snyder LLC’s holdings in Allergan were worth $1,349,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also added to or reduced their stakes in the business. Legacy Private Trust Co. boosted its holdings in shares of Allergan by 86.4% during the fourth quarter. Legacy Private Trust Co. now owns 8,442 shares of the company’s stock valued at $1,614,000 after acquiring an additional 3,912 shares during the period. Modus Advisors LLC acquired a new stake in Allergan in the fourth quarter worth about $914,000. Allred Capital Management LLC acquired a new stake in Allergan in the fourth quarter worth about $92,000. Tuttle Tactical Management lifted its holdings in Allergan by 40.1% in the fourth quarter. Tuttle Tactical Management now owns 8,146 shares of the company’s stock worth $1,557,000 after purchasing an additional 2,332 shares during the period. Finally, BKD Wealth Advisors LLC acquired a new stake in Allergan in the fourth quarter worth about $288,000. Hedge funds and other institutional investors own 82.28% of the company’s stock.

Several research firms recently weighed in on AGN. Wells Fargo & Co reaffirmed an “outperform” rating and issued a $184.00 price objective (up previously from $176.00) on shares of Allergan in a report on Monday, September 30th. ValuEngine downgraded shares of Allergan from a “hold” rating to a “sell” rating in a report on Wednesday, October 30th. Finally, UBS Group downgraded shares of Allergan from a “buy” rating to a “neutral” rating and upped their price objective for the stock from $189.00 to $203.00 in a report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, sixteen have assigned a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $175.90.

NYSE AGN opened at $193.85 on Thursday. The stock’s 50-day moving average price is $189.36 and its two-hundred day moving average price is $173.36. The company has a current ratio of 1.00, a quick ratio of 0.88 and a debt-to-equity ratio of 0.33. The company has a market cap of $63.21 billion, a PE ratio of 11.61, a PEG ratio of 1.89 and a beta of 1.64. Allergan plc has a 1 year low of $114.27 and a 1 year high of $194.61.

Allergan (NYSE:AGN) last issued its earnings results on Tuesday, November 5th. The company reported $4.25 earnings per share for the quarter, meeting analysts’ consensus estimates of $4.25. The company had revenue of $4.03 billion for the quarter, compared to the consensus estimate of $3.88 billion. Allergan had a positive return on equity of 9.08% and a negative net margin of 58.50%. The firm’s quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $4.25 EPS. Research analysts forecast that Allergan plc will post 16.88 EPS for the current fiscal year.

About Allergan

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.

Featured Story: What is the significance of the death cross?

Want to see what other hedge funds are holding AGN? Visit to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with's FREE daily email newsletter.